What Is Selank? Benefits, Mechanism & Safety

Selank research peptide vial with dosage and benefit information

If you’ve been browsing peptide communities and keep seeing “Selank,” the natural next question is: What is Selank? Selank is a tuftsin-derived synthetic peptide studied mainly for anxiety reduction and “calm focus,” with additional neuroimmune research showing cytokine and gene-expression effects. This evidence-based guide from PeptideDosages.com[1] separates what’s measured (human trials, biomarkers, imaging) from what’s inferred (mechanisms and “nootropic” narratives). [2]

Fast Answer / Executive Summary

Fast Answer: Selank is a synthetic heptapeptide (TKPRPGP) derived from the immune peptide tuftsin and studied primarily for anxiety-reducing (anxiolytic), cognition-supporting (nootropic), and immunomodulatory effects. Most human research is from Russia and often used intranasally; in the U.S. it’s generally sold as research-grade and is not FDA-approved. [3]

Core Concepts & Key Entities

Selank is a synthetic regulatory heptapeptide with the amino-acid sequence Thr‑Lys‑Pro‑Arg‑Pro‑Gly‑Pro (TKPRPGP). In chemical references you’ll also see identifiers like a molecular weight around 751.9 g/mol and the IUPAC condensed form H‑Thr‑Lys‑Pro‑Arg‑Pro‑Gly‑Pro‑OH. [4]

Selank was designed and produced at the Institute of Molecular Genetics[5] (within the Russian Academy of Sciences[6]) in cooperation with the V.V. Zakusov Research Institute of Pharmacology[7]. This origin matters because much of Selank’s indexed literature comes from that research ecosystem, including intranasal delivery and anxiety-focused outcomes. [8]

Tuftsin—the biological “parent idea” behind Selank—is a natural tetrapeptide (Thr‑Lys‑Pro‑Arg) located in the Fc domain of IgG and associated with immune and phagocyte-related activity in classic immunology reviews. Selank extends that tuftsin core by adding Pro‑Gly‑Pro to improve metabolic stability and duration in vivo, which is why Selank is often described as “tuftsin + a stability tail.” [9]

Selank at a glance

Selank’s topic cluster is easiest to navigate when you separate identity, intent, and evidence.

What it is: a synthetic tuftsin analog (heptapeptide). [10]
What it’s studied for (best-supported): anxiety reduction and anxiety-asthenic symptom clusters in small human studies. [11]
What it’s studied for (secondary): neuroimmune signaling (cytokines) and mechanistic brain readouts (gene expression, functional connectivity). [12]
What it is not: an FDA-approved anxiety medication in the U.S. [13]

A simple evidence ladder for Selank claims

This framework is “information gain” you can reuse for almost any Selank claim, whether it comes from a paper, a clinic blog, or a vendor page.

1) Clinical outcomes: symptom scales and functioning (best for “does it reduce anxiety?”). [14]
2) Human biomarkers: cytokines/immune patterns in humans (valuable, but not the same as symptom relief). [15]
3) Human brain readouts: EEG/fMRI connectivity changes (mechanistic clues, not automatic clinical benefit). [16]
4) Animal behavior: stress and maze models (directional evidence; imperfect translation). [17]
5) Molecular mechanisms: gene-expression and receptor-level hypotheses (plausibility). [18]

If a claim is “big,” but it lives mostly at levels 4–5, treat it as plausible—not proven.

What research suggests about how Selank may work

Selank is best described as multi-system modulation with a strong GABA-related hypothesis, not a single-target drug. The most-cited mechanistic strands touch inhibitory signaling (GABA), arousal circuitry, monoamines, neurotrophins (BDNF), and immune signaling. [19]

GABA-related signaling and neurotransmission gene expression

A widely cited mechanistic study investigated Selank’s effects on neurotransmission-related gene expression in rat frontal cortex after intranasal administration, comparing Selank to GABA and analyzing 84 genes tied to neurotransmission (including GABA receptor subunits/transporters and dopamine/serotonin receptors). The authors reported broad alterations and concluded that one possible mechanism is allosteric modulation of the GABAergic system. [18]

This matters because benzodiazepines—classic anxiolytics—act via GABA-A receptor modulation and produce well-known sedative effects and dependence risks. Selank research often positions Selank as having an anxiolytic profile with fewer of those typical benzodiazepine drawbacks, although that conclusion should be treated as “suggestive” given the limited size of the human trial base. [20]

Calm focus and arousal circuitry

Selank’s community nickname (“calm focus”) is consistent with a simple clinical idea: reducing anxious arousal can free up attention, working memory, and task initiation, especially for people whose cognition collapses under stress. Mechanistic papers also discuss downstream involvement of dopamine/serotonergic systems and arousal-regulation signals, which can support the plausibility of “calm without fog” as a phenotype. [18]

BDNF and synaptic plasticity

A PubMed-indexed rat study reports that intranasal Selank regulates BDNF expression in the rat hippocampus in vivo. This is mechanistically interesting, but it remains preclinical and should not be translated into guaranteed human “BDNF boosting.” [21]

Neuroimmune signaling and cytokines

Selank’s “immune angle” is not just marketing. A human immunology study involving patients with anxiety-asthenic disorders reported changes in Th1/Th2 cytokine balance in vivo after 14 days of Selank and described IL‑6–related findings in vitro. [15]

In animal work, a social-stress model study reported that Selank administration in stressed rats was associated with reductions toward control values for multiple cytokines (including IL‑1β, IL‑6, TNF‑α, and TGF‑β1 in that experiment). This supports “stress-protective, immune-linked” plausibility, while remaining animal data. [17]

What benefits have the strongest support?

Selank benefit claims are easiest to evaluate when you sort them into supported vs plausible vs overstated.

Anxiety reduction

Anxiety reduction has the strongest direct human signal for Selank, but the evidence base is limited. A 2008 randomized controlled trial studied 62 patients with generalized anxiety disorder (GAD) and neurasthenia, comparing Selank (30 patients) to medazepam (32 patients). The abstract reports that anxiolytic effects were similar, while Selank was also described as having antiasthenic and psychostimulant effects. [14]

Antiasthenic effects and “energy without heavy sedation”

Selank’s “antiasthenic” reputation largely traces back to that same clinical narrative—improvement in fatigue-like/asthenic symptoms alongside anxiolysis. It’s a real signal in the cited clinical abstract, but it is not the same thing as a stimulant mechanism or guaranteed energy for everyone. [14]

What benefits are plausible but not proven?

Cognition under stress

Selank’s nootropic reputation may be secondary to anxiety reduction: less anxiety often looks like improved cognition. The clearest indexed human “brain mechanism” paper is a 2020 study in 52 healthy participants using resting-state fMRI before and after injection of Selank, Semax, or placebo, reporting differences in functional connectivity involving the right amygdala and right temporal regions. That is a mechanistic signal—not a cognitive performance endpoint. [16]

Sleep and stress recovery

Some mechanistic discussions suggest Selank may influence sleep-wake or arousal circuitry, but sleep improvement is not yet a primary “clinically established” use based on strong trials. Treat sleep claims as plausible, monitorable, and highly individual. [18]

Safety, risks, and what the evidence does not guarantee

Selank sits in a “gray zone”: it’s neuroactive, frequently self-sourced, and not backed by the large, long-term safety databases that exist for approved drugs. That’s why responsible guidance emphasizes risk management over promise.

The risk picture, based on the strongest accessible sources:

Regulatory status: Selank is not an FDA-approved drug product in the U.S. [13]
Immunogenicity / impurities: The U.S. Food and Drug Administration[22] has explicitly stated that compounded drugs containing selank acetate (TP‑7) may pose immunogenicity risks for certain routes due to potential aggregation and peptide-related impurities, and that the agency lacks important safety information for humans. [13]
Evidence gaps: Human studies exist, but they are limited and do not map cleanly onto years-long, real-world use for broad populations. [11]

Day-to-day side effects discussed in communities (headaches, irritability, sleep disruption, local irritation with injectable protocols) are largely anecdotal, which is exactly why structured tracking and clear stop rules matter.

A safe, evidence-aligned stance is: treat Selank as experimental, keep variables minimal, and avoid stacking multiple new psychoactive substances at once. [13]

Step-by-Step / How-To

Selank conversations get messy because people mix (1) published intranasal studies, (2) clinic-style “peptide therapy” language, and (3) research-grade lyophilized vials sold online. The steps below keep intent and evidence aligned.

Choose the Selank format you mean

Selank is most often discussed in two formats: intranasal solutions (common in published research) and reconstituted vial protocols (common in the peptide market). Route matters because intranasal delivery is described in scientific literature as a non-invasive approach that may allow certain substances more direct access to the CNS via nasal pathways, depending on molecule and formulation. [23]

Anchor expectations to human studies first

If your goal is anxiety relief, start with the human studies rather than the marketing ecosystem.

A 2008 randomized controlled trial in 62 patients compared Selank to medazepam and reported similar anxiolytic effects, with additional antiasthenic/psychostimulant effects attributed to Selank. [14]
A human immunology study reported Th1/Th2 cytokine balance changes after 14 days of Selank in anxiety-asthenic disorders. [15]
A 2020 resting-state fMRI study in 52 healthy participants reported functional connectivity changes after Selank (and Semax) compared with placebo, involving the right amygdala and right temporal regions. [16]

Key takeaway: Selank has a real signal, but it is not a high-certainty, modern, large-scale evidence base.

Do a baseline week first

Baseline tracking is the cheapest “upgrade” you can make to any protocol.

Track for 7 days before changes: – Sleep quality (0–10) – Anxiety intensity (0–10) – Focus blocks (count) – One note on major stressors each day

This prevents you from confusing normal week-to-week variance with a “peptide effect.”

Use an intent-based protocol framework

Most people pursue Selank for one of these intents:

Calm without sedation
Stress resilience
Cognition under pressure (usually via reduced anxiety load)

Treat Selank as an anxiolytic-first peptide and judge cognition secondarily, unless you have a clear, measurable cognition endpoint. [24]

Understand “Selank acetate / TP‑7” before you shop or compare

“Selank acetate (TP‑7)” appears in regulatory and compounding contexts. The FDA’s wording on selank acetate emphasizes potential immunogenicity risks related to aggregation/impurities and insufficient safety information—signals that quality and characterization matter as much as dosing math. [13]

Separately, research papers sometimes describe Selank as a diacetate salt in experimental preparation, reinforcing that “Selank” in literature and “Selank” in commerce are not automatically equivalent. [18]

If you’re using vials, make dosing math boring and explicit

Most dosing mistakes come from unit confusion.

Educational protocol pages commonly use: – 5 mg vial + 3.0 mL → ~1.67 mg/mL, where 1 unit on a U‑100 syringe ≈ 16.7 mcg
– 10 mg vial + 3.0 mL → ~3.33 mg/mL, where 1 unit on a U‑100 syringe ≈ 33.3 mcg [25]

Vial size	Reconstitution example	Concentration	1 unit on U‑100 ≈	300 mcg dose ≈	500 mcg dose ≈
5 mg	3.0 mL	1.67 mg/mL	16.7 mcg	18 units (0.18 mL)	30 units (0.30 mL)
10 mg	3.0 mL	3.33 mg/mL	33.3 mcg	9 units (0.09 mL)	15 units (0.15 mL)

Those values match the Quickstart math shown on the Selank vial protocol pages. [25]

A universal conversion that prevents errors:

mL to draw = (target dose in mcg) ÷ (concentration in mcg per mL)
Units on U‑100 = mL ÷ 0.01

Use conservative titration and structured cycling

Educational Selank protocols commonly start around 300 mcg/day and titrate toward 500 mcg/day, often framed in 4-week cycles and/or “5 days on, 2 days off” schedules, with a common “4 weeks on, 4 weeks off” cycling pattern to reduce habituation concerns. [25]

Whether tachyphylaxis is “proven” for Selank isn’t settled in the same way it is for many approved drugs, but cycling provides a practical structure for comparing baseline vs on-cycle signals.

Store and handle Selank like quality control is part of the protocol

Protocol pages commonly recommend: – Lyophilized storage frozen long-term (e.g., around −20°C) – Refrigeration after reconstitution (2–8°C) – Avoiding freeze–thaw cycles – Gentle swirling instead of shaking [25]

Handling and storage also show up on vendor pages because they affect stability and degradation risk. [26]

Vetting a Selank supplier in two minutes

You can’t “out-optimize” a low-quality peptide. Before you care about protocol nuance, confirm basics:

Ask for a batch COA and confirm it matches the exact lot/product.
Confirm identity details (sequence/salt form) and stated purity. [26]
Prefer vendors that disclose standardized identifiers (CAS, molecular weight) and storage guidance. [27]
Avoid sources mixing medical claims with “research use only” disclaimers—regulatory mismatch is a quality red flag. [28]

Comparison / Alternatives

Selank sits in a middle zone: discussed like a “calm nootropic,” while first-line anxiety treatment evidence often points to psychotherapy (and, when needed, regulated pharmaceuticals). A comparison helps match the right tool to the right intent.

Option	Best fit for	Human evidence for anxiety	Typical downsides	Sedation / dependence risk	Regulatory status (US)
Selank	Calm focus / stress-resilience experiments	Limited (older, smaller studies)	Quality variability; unclear long-term safety	Appears lower than benzodiazepines in available reports, but not proven “risk-free”	Not FDA-approved; compounding safety concerns noted for selank acetate
Benzodiazepines (e.g., diazepam)	Short-term, acute anxiety relief	Strong	Drowsiness, cognitive impairment; withdrawal risk with long-term use	Known dependence/withdrawal risk	FDA-approved medicines (by product)
CBT	GAD/worry loops; long-term skills	Strong	Time/effort/access constraints	None	Standard of care
L-theanine	Mild, supplement-level stress/anxiety support	Moderate	Smaller effects; supplement quality varies	Low	Dietary supplement

Evidence anchors for the table: Selank human anxiolytic comparison and “antiasthenic” signal (2008 RCT), Selank immune biomarker study (14-day course), and FDA compounding risk language for selank acetate; benzodiazepine adverse effects and risks; CBT meta-analysis support; and L-theanine systematic review findings. [29]

Templates / Checklist / Example

Use this copy-ready checklist to plan a Selank research protocol without drifting into guesswork.

Define your primary outcome (e.g., “reduce baseline anxiety” vs “improve focus under stress”).
Pick one route/form (intranasal vs vial-based) so you’re not mixing variables.
Verify source quality (COA, identity specs, storage/shipping conditions).
Start conservatively and change only one variable at a time.
Track daily signals (sleep, anxiety rating, focus blocks, side effects).
Cycle the protocol (planned breaks) to compare baseline vs on-cycle.
Avoid adding multiple new psychoactive compounds simultaneously.
Stop and reassess if adverse effects appear or anxiety worsens.

Example tracking template (copy/paste):

Date:
Dose & route:
Sleep (0–10):
Anxiety (0–10):
Focus blocks (count):
Physical tension (0–10):
Notable stressors today:
Side effects / notes:

FAQs

What is Selank used for?

What is Selank used for? Selank is used in research and off-label discussion mainly for anxiety reduction and anxiety-asthenic symptoms, and it’s commonly positioned as “calm focus” rather than sedation. Human evidence includes a randomized trial comparing Selank with medazepam in GAD/neurasthenia and a human study reporting immune marker changes after a 14-day course. [11]

Is Selank the same thing as Selank acetate or TP‑7?

Is Selank the same thing as Selank acetate or TP‑7? Selank acetate (often labeled TP‑7) generally refers to Selank supplied as an acetate salt form used in bulk substances and product manufacturing. It’s still Selank at the peptide level, but purity, aggregation, and impurities can vary by manufacturer—one reason regulators focus on compounding risk rather than assuming equivalence. [30]

Is Selank FDA-approved in the United States?

Is Selank FDA-approved in the United States? Selank is not an FDA-approved prescription drug in the U.S., and it commonly appears as a research-grade peptide online. The FDA has publicly stated that compounded drugs containing selank acetate may pose immunogenicity risks due to aggregation and peptide-related impurities, and that the agency lacks important safety information for human administration. [13]

Does Selank work like a benzodiazepine?

Does Selank work like a benzodiazepine? Selank is not a benzodiazepine, but some studies describe overlapping anxiolytic profiles or GABA-related mechanisms. A clinical trial abstract reports similar anxiolytic effects between Selank and medazepam, and mechanistic work in rats links Selank to gene-expression changes consistent with a GABAergic modulation hypothesis. That supports “anxiolytic” framing but does not prove equivalence in risks or long-term outcomes. [31]

Intranasal or injectable: how is Selank typically used in studies?

Intranasal or injectable: how is Selank typically used in studies? Selank is often administered intranasally in the research literature, while modern peptide-market use also includes reconstituted vial protocols. Intranasal delivery is discussed in the scientific literature as a route that can, in some contexts, help deliver certain substances to the CNS via nasal pathways, but outcomes depend on formulation and molecule. [32]

Selank vs Semax: what’s the difference?

Selank vs Semax: what’s the difference? Selank is typically positioned as the “calming/anxiolytic” peptide, while Semax is typically positioned as the “focus/nootropic” peptide. A human resting-state fMRI study evaluated both peptides in the same design and reported differences in functional connectivity involving the amygdala and temporal regions shortly after administration. [16]

Next Steps

If you remember only one thing: Selank is best thought of as a tuftsin-derived “calm nootropic” with limited but real human signal—and major quality/regulatory caveats. [33]

For protocol math and vial-specific guidance, use these internal pages: – Selank 5 mg vial dosage protocol [34]
– Selank 10 mg vial dosage protocol [35]

If you’re purchasing Selank strictly for research/lab use, commonly referenced vendor pages are from Pure Lab Peptides[36]: – Selank 5mg [37]
– Selank 10mg [38]

Educational note: This article is for information only and is not medical advice. Selank products sold online are frequently labeled for research use only and not intended for human consumption. [26]

[1] [11] [14] [24] [29] [31] [33] https://pubmed.ncbi.nlm.nih.gov/18454096/

https://pubmed.ncbi.nlm.nih.gov/18454096/

[2] [3] [6] [8] [10] [12] [18] [19] [20] [22] [32] https://pmc.ncbi.nlm.nih.gov/articles/PMC4757669/

https://pmc.ncbi.nlm.nih.gov/articles/PMC4757669/

[4] https://pubchem.ncbi.nlm.nih.gov/compound/Selank

https://pubchem.ncbi.nlm.nih.gov/compound/Selank

[5] [9] https://pubmed.ncbi.nlm.nih.gov/2667894/

https://pubmed.ncbi.nlm.nih.gov/2667894/

[7] [13] [28] [30] Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA

https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks

[15] https://pubmed.ncbi.nlm.nih.gov/18577961/

https://pubmed.ncbi.nlm.nih.gov/18577961/